NNFN Stock Overview A biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
MannKind Corporation Competitors Price History & Performance
Summary of share price highs, lows and changes for MannKind Historical stock prices Current Share Price US$5.56 52 Week High US$7.00 52 Week Low US$2.97 Beta 1.28 1 Month Change -14.29% 3 Month Change -7.05% 1 Year Change 58.20% 3 Year Change 47.51% 5 Year Change 352.54% Change since IPO -88.89%
Recent News & Updates
MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®) Dec 16
Third quarter 2024 earnings released: EPS: US$0.042 (vs US$0.006 in 3Q 2023) Nov 08
MannKind Corporation Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases Nov 05
MannKind Corporation to Report Q3, 2024 Results on Nov 07, 2024 Nov 01
Mannkind Corporation Announces Top-Level 30-Week Results from Its Phase 4 Inhale-3 Study Oct 01
MannKind Corporation Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease Sep 18 See more updates
MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®) Dec 16
Third quarter 2024 earnings released: EPS: US$0.042 (vs US$0.006 in 3Q 2023) Nov 08
MannKind Corporation Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases Nov 05
MannKind Corporation to Report Q3, 2024 Results on Nov 07, 2024 Nov 01
Mannkind Corporation Announces Top-Level 30-Week Results from Its Phase 4 Inhale-3 Study Oct 01
MannKind Corporation Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease Sep 18
Insufficient new directors Sep 01
Mannkind Corporation Announces Board Changes, September 30, 2024 Aug 14
New minor risk - Shareholder dilution Aug 08
Second quarter 2024 earnings released: US$0.007 loss per share (vs US$0.02 loss in 2Q 2023) Aug 08
New minor risk - Share price stability Aug 06
MannKind Corporation to Report Q2, 2024 Results on Aug 07, 2024 Jul 31
MannKind Corporation Announces Positive 17-Week Results from the INHALE-3 Study Jun 22
First quarter 2024 earnings released: EPS: US$0.039 (vs US$0.037 loss in 1Q 2023) May 09
New major risk - Financial position May 09
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease May 08
MannKind Corporation to Report Q1, 2024 Results on May 08, 2024 May 03 MannKind Corporation to Proceed with Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases
MannKind Corporation, Annual General Meeting, May 15, 2024 Apr 06 MannKind Corporation Announces Chief Financial Officer Changes, Effective April 22, 2024
MannKind Corporation Announces INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps Mar 11
Full year 2023 earnings released: US$0.045 loss per share (vs US$0.34 loss in FY 2022) Feb 28
MannKind Corporation to Report Q4, 2023 Results on Feb 27, 2024 Feb 21
MannKind Corporation Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza® Feb 15
Third quarter 2023 earnings released: EPS: US$0.006 (vs US$0.056 loss in 3Q 2022) Nov 08
MannKind Corporation Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living with Type 1 Diabetes Nov 07
MannKind Corporation to Report Q3, 2023 Results on Nov 07, 2023 Nov 01
Second quarter 2023 earnings released: US$0.02 loss per share (vs US$0.11 loss in 2Q 2022) Aug 08
MannKind Corporation to Report Q2, 2023 Results on Aug 07, 2023 Aug 01
Mannkind Corporation Launches Inhale-3 Study to Address the Most Important Unmet Need in Adults Living with Type 1 Diabetes (T1d) Jun 23
Dr. Burkhard Blank Joins MannKind Corporation as Executive Vice President of Research & Development and Chief Medical Officer May 25
First quarter 2023 earnings released: US$0.037 loss per share (vs US$0.10 loss in 1Q 2022) May 10
Forecast to breakeven in 2024 Apr 27
Full year 2022 earnings released: US$0.34 loss per share (vs US$0.33 loss in FY 2021) Feb 24
Forecast to breakeven in 2024 Feb 24
MannKind Corporation to Report Q4, 2022 Results on Feb 23, 2023 Feb 17
MannKind Corporation Announces its Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung Disease Jan 24
High number of new directors Nov 16
Third quarter 2022 earnings released: US$0.056 loss per share (vs US$0.018 loss in 3Q 2021) Nov 09
Mannkind Corporation Announces Resignation of Alejandro Galindo as Executive Vice President – Endocrine Business Unit, Effective October 21, 2022 Sep 27
MannKind Corporation Successfully Completes Phase 1 Study of Inhaled Clofazimine Sep 07
Second quarter 2022 earnings released: US$0.11 loss per share (vs US$0.14 loss in 2Q 2021) Aug 11
MannKind Corporation to Report Q2, 2022 Results on Aug 09, 2022 Aug 03 MannKind’s Technosphere® Inhalation Platform Utilized in FDA-Approved Tyvaso DPI™ May 25
Zealand Pharma A/S (CPSE:ZEAL) entered into an agreement to acquire V-Go® Insulin Delivery Device from Zealand Pharma for $10 million. May 18
First quarter 2022 earnings released: US$0.10 loss per share (vs US$0.052 loss in 1Q 2021) May 07
High number of new directors Apr 27
MannKind Corporation, Annual General Meeting, May 10, 2022 Mar 31
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Feb 26
MannKind Corporation Provides Update on Tyvaso DPI New Drug Application Feb 25
MannKind Corporation to Report Q4, 2021 Results on Feb 24, 2022 Feb 22
Forecast to breakeven in 2024 Jan 01
Third quarter 2021 earnings released: US$0.018 loss per share (vs US$0.049 loss in 3Q 2020) Nov 10
No longer forecast to breakeven Aug 22
High number of new and inexperienced directors Aug 20
No longer forecast to breakeven Aug 13
Second quarter 2021 earnings released: US$0.14 loss per share (vs US$0.048 loss in 2Q 2020) Aug 13
First quarter 2021 earnings released: US$0.052 loss per share (vs US$0.044 loss in 1Q 2020) May 14
Full year 2020 earnings released: US$0.26 loss per share (vs US$0.27 loss in FY 2019) Feb 26
Revenue beats expectations Feb 26
MannKind Corporation to Report Q4, 2020 Results on Feb 25, 2021 Feb 19
New 90-day high: €5.44 Feb 06
Mannkind Corporation and Vertice Pharma to Co-Promote Thyquidity Oral Solution Dec 19
New 90-day high: €2.60 Dec 16
Chief Commercial Officer recently bought €83k worth of stock Dec 13
MannKind Corporation Appoints James S. Shannon as the Chairman of the Board of Directors Dec 11
MannKind Corporation Appoints Sabrina Kay Ed.D. to Its Board of Directors Dec 01
New 90-day high: €2.10 Nov 11
Revenue misses expectations Nov 06
Third quarter 2020 earnings released: US$0.049 loss per share Nov 06
MannKind Corporation to Report Q3, 2020 Results on Nov 04, 2020 Oct 30
New 90-day high: €1.75 Oct 24
New 90-day high: €1.66 Sep 22
First half earnings released Aug 06 Shareholder Returns NNFN DE Biotechs DE Market 7D -11.0% -1.2% -1.4% 1Y 58.2% -13.2% 8.0%
See full shareholder returns
Return vs Market: NNFN exceeded the German Market which returned 8.1% over the past year.
Price Volatility Is NNFN's price volatile compared to industry and market? NNFN volatility NNFN Average Weekly Movement 5.5% Biotechs Industry Average Movement 6.7% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.9% 10% least volatile stocks in DE Market 2.5%
Stable Share Price: NNFN has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: NNFN's weekly volatility (5%) has been stable over the past year.
About the Company MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company’s product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF).
Show more MannKind Corporation Fundamentals Summary How do MannKind's earnings and revenue compare to its market cap? NNFN fundamental statistics Market cap €1.58b Earnings (TTM ) €20.81m Revenue (TTM ) €257.82m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) NNFN income statement (TTM ) Revenue US$267.20m Cost of Revenue US$75.07m Gross Profit US$192.14m Other Expenses US$170.57m Earnings US$21.57m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) 0.078 Gross Margin 71.91% Net Profit Margin 8.07% Debt/Equity Ratio -108.6%
How did NNFN perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/18 13:14 End of Day Share Price 2024/12/18 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources MannKind Corporation is covered by 26 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Thomas Russo Baird Stephen V. Byrne BofA Global Research null null BTIG
Show 23 more analysts 
